STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT

In many ways, arterial hypertension and obesity determine the likelihood of a severe course and lethal outcomes in COVID-19. This fact justifies the expediency of an early use of drugs with a direct antiviral action, the analysis of their efficacy not only in the acute, but also in the postcovid per...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, Yu. A. Kostina, M. S. Iskandyarova, E. V. Negodnova, V. V. Eremeev, L. F. Sabirov, E. V. Semeleva
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University 2021-12-01
Sarja:Farmaciâ i Farmakologiâ (Pâtigorsk)
Aiheet:
favipiravir
covid-19
novel coronavirus infection
areplivir
Linkit:https://www.pharmpharm.ru/jour/article/view/981
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia